Microsatellite-stable colorectal cancer with low chromosomal instability responds to immunotherapy and is sensitized by proteasome inhibition

Microsatellite-stable (MSS) colorectal cancer (CRC) is typically considered poorly responsive to immunotherapy. This study aims to identify characteristics of MSS CRC patients who are likely to benefit from immunotherapy and to investigate effective agents that could improve immunotherapy efficacy for this subgroup. We performed an integrated analysis combining single-cell RNA sequencing, bulk RNA sequencing, and whole-exome sequencing data from patient-derived organoids and tumor tissues to identify a specific MSS subtype that potentially benefits from immunotherapy. To validate our findings, we employed a humanized mouse model to assess the effects of anti-programmed cell death protein 1 (PD-1) therapy in different CRC subtypes. Subsequently, we conducted drug screening to identify compounds that could inhibit mismatch repair capacity. In vivo models were developed for further validation. Western blot and co-immunoprecipitation were employed to investigate the molecular mechanisms by which bortezomib enhances immunotherapy efficacy. Our analysis revealed that MSS CRC with low chromosomal instability (CIN), characterized by a low fraction of genome altered (FGA) level, displayed heightened immunogenicity and a gene expression profile similar to CRC with microsatellite instability (MSI), indicating potential responsiveness to immunotherapy. In the humanized mouse model, anti-PD-1 therapy significantly increased immune cell activation within the FGA low MSS CRC subtype. Analysis of clinical single-cell RNA sequencing samples from patients undergoing anti-PD-1 therapy further indicated that FGA low MSS CRC patients were more likely to respond to immunotherapy. Furthermore, we identified bortezomib, a proteasome inhibitor, as a promising agent to potentiate immunotherapy in FGA low MSS CRC by promoting anti-tumor immunity in humanized mouse models. Mechanistically, bortezomib was found to inhibit tumor cells’ DNA mismatch repair by inducing autophagic degradation of mismatch repair proteins and activate the cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) pathway to evoke an endogenous anti-tumor immune response. Our study identified MSS CRC with low CIN as potential candidates for immunotherapy and highlighted the proteasome inhibitor bortezomib as a strategic addition to augment immunotherapy efficacy for this specific subset.

Authors

Institutions

Publication Details

Journal
Genome Medicine
Published
2026-11-13
DOI
https://doi.org/10.1186/s13073-026-01827-3
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Microsatellite-stable colorectal cancer with low chromosomal instability responds to immunotherapy and is sensitized by proteasome inhibition

Jinying Jia, Pengju Chen, Mengyuan Shi, Zhuang Sun et al.
2 links
Genome Medicine
Cancer Immunotherapy and Biomarkers
article

Microsatellite-stable colorectal cancer with low chromosomal instability responds to immunotherapy and is sensitized by proteasome inhibition

Jinying Jia, Pengju Chen, Mengyuan Shi, Zhuang Sun, Dengbo Ji, Hongquan Zhang, Peng Yang, Zhaoya Gao, Xunan Liu, Guo An, Jin Gu
article en

Abstract

Microsatellite-stable (MSS) colorectal cancer (CRC) is typically considered poorly responsive to immunotherapy. This study aims to identify characteristics of MSS CRC patients who are likely to benefit from immunotherapy and to investigate effective agents that could improve immunotherapy efficacy for this subgroup. We performed an integrated analysis combining single-cell RNA sequencing, bulk RNA sequencing, and whole-exome sequencing data from patient-derived organoids and tumor tissues to identify a specific MSS subtype that potentially benefits from immunotherapy. To validate our findings, we employed a humanized mouse model to assess the effects of anti-programmed cell death protein 1 (PD-1) therapy in different CRC subtypes. Subsequently, we conducted drug screening to identify compounds that could inhibit mismatch repair capacity. In vivo models were developed for further validation. Western blot and co-immunoprecipitation were employed to investigate the molecular mechanisms by which bortezomib enhances immunotherapy efficacy. Our analysis revealed that MSS CRC with low chromosomal instability (CIN), characterized by a low fraction of genome altered (FGA) level, displayed heightened immunogenicity and a gene expression profile similar to CRC with microsatellite instability (MSI), indicating potential responsiveness to immunotherapy. In the humanized mouse model, anti-PD-1 therapy significantly increased immune cell activation within the FGA low MSS CRC subtype. Analysis of clinical single-cell RNA sequencing samples from patients undergoing anti-PD-1 therapy further indicated that FGA low MSS CRC patients were more likely to respond to immunotherapy. Furthermore, we identified bortezomib, a proteasome inhibitor, as a promising agent to potentiate immunotherapy in FGA low MSS CRC by promoting anti-tumor immunity in humanized mouse models. Mechanistically, bortezomib was found to inhibit tumor cells’ DNA mismatch repair by inducing autophagic degradation of mismatch repair proteins and activate the cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) pathway to evoke an endogenous anti-tumor immune response. Our study identified MSS CRC with low CIN as potential candidates for immunotherapy and highlighted the proteasome inhibitor bortezomib as a strategic addition to augment immunotherapy efficacy for this specific subset.

Genome Medicine
University of Southern California (US), Peking University (CN), Peking University Cancer Hospital (CN), Peking University Shougang Hospital (CN), State Key Laboratory of Molecular Oncology (CN)
National Natural Science Foundation of China
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon